The Chemours Company filings document formal disclosures for a NYSE-listed global chemistry company with businesses in Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials. Recent Form 8-K reports furnish operating results and financial condition updates, including segment commentary on Opteon refrigerants, TiO2 pigment, and other specialty-chemistry markets.
Regulatory filings also cover capital-structure actions, including senior unsecured notes, indentures, guarantees, and redemption of outstanding debt. Definitive proxy materials document board structure, director elections, advisory compensation votes, auditor ratification, equity-incentive plan approval, and other shareholder voting matters.
Chemours Co reported that SVP, GC & Corp. Secretary Kristine M. Wellman had 391 shares of common stock automatically withheld on August 1, 2026 at $16.61 per share to satisfy tax obligations on vesting restricted stock units and dividend equivalent units. Footnotes state that no shares were sold, and her direct holdings, including shares, restricted stock units and dividend equivalent units, total 74,418.8998 shares after this transaction.
Chemours Co director Courtney Mather received a grant of deferred stock units as part of board compensation. On this date, Mather acquired 1,401 deferred stock units, each economically equivalent to one share of Chemours common stock, at a reference value of $20.52 per unit.
The award increases Mather’s directly held deferred stock units to a total of 8,983.8481 units, including dividend equivalent units. These deferred stock units become payable in shares of common stock in the first month after Mather’s termination of service as a director, so they function as long-term, non-cash compensation rather than an open-market purchase.
The Chemours Company entered into a proposed settlement with the U.S. Environmental Protection Agency and the West Virginia Department of Environmental Protection to resolve claims relating to PFAS emissions and other alleged activities at several facilities. Chemours agreed to pay a $22.5 million civil penalty in three annual installments, beginning within 30 days after court approval of a Consent Decree, and to fund $90 million of additional mitigation projects over 15 years to reduce PFAS emissions and support alternative drinking water solutions.
The company will expand off-site drinking water programs in West Virginia, Ohio and New Jersey, which it expects will increase existing environmental reserves. Chemours also resolved litigation brought by the West Virginia Rivers Coalition for less than $1 million. The settlement, which does not constitute an admission of liability or fault by Chemours, remains subject to public notice, comment and final court approval.
CRANSTON MARY B reported acquisition or exercise transactions in this Form 4 filing.
Chemours Co director Mary B. Cranston received an equity grant of 7,182 shares of common stock on May 6. The award was granted at no cash cost to her, reflecting stock-based compensation rather than an open-market purchase.
After this grant and an adjustment to correct an administrative error in prior filings, her direct and deferred holdings now total 106,830.0129 shares, including deferred stock units and related dividend equivalent units.
Chemours director Leslie M. Turner received a grant of 7,182 stock units of Chemours common stock on May 6, 2026. The units were awarded at no cash cost and increase Turner’s direct holdings to 24,603.3891 stock units.
According to the footnotes, these stock units, including deferred stock units and dividend equivalent units, will convert one-for-one into Chemours common stock when Turner separates from service on the Board. This reflects routine equity-based board compensation rather than an open-market purchase.
Chemours Co director Pamela Fletcher received a grant of 7,182 shares of Common Stock on May 6, 2026, as a stock award. The shares were awarded at a price of $0.00 per share as compensation, not an open-market purchase.
The award represents stock units that will convert one-for-one into Chemours common stock upon her separation from service on the Board and includes deferred stock units and dividend equivalent units. After this grant, Fletcher directly holds a total of 32,382.9997 shares of Chemours common stock.
Chemours director Alister Cowan reported a grant of 7,182 stock units of Chemours common stock. The units were acquired at a stated price of $0.00 per share as a compensation award. Following this grant, Cowan directly holds 43,881.0397 shares or stock units in total.
The granted stock units, including deferred stock units and dividend equivalent units, will convert one-for-one into Chemours common stock when Cowan separates from service on the Board.
Chemours director Courtney Mather received a grant of 7,182 stock units of Chemours common stock on May 6, 2026. These stock units will convert one-for-one into Chemours common shares upon separation from service on the Board and include deferred and dividend equivalent units. Following this award, Mather holds a total of 21,642.7173 stock units directly.
Chemours Co director Erin N. Kane received a grant of 7,182 Chemours common stock units as board compensation. The award was recorded at a price of $0.00 per unit and increases Kane’s directly held stock units to 74,062.9086.
The footnotes explain these are stock units that will convert one-for-one into Chemours common shares when Kane separates from service on the Board, and that the total includes both deferred stock units and related dividend equivalent units. This is a non-cash, routine equity award rather than an open-market purchase.
Chemours Co director Livingston Satterthwaite received an equity award of 7,182 stock units of Chemours common stock as board compensation. The units were granted at no cash cost to the director and will convert one-for-one into Chemours common shares upon separation from board service.
The award includes deferred stock units and related dividend equivalent units, increasing Satterthwaite’s directly held balance to 30,807.855 shares and stock units combined after this transaction.